- Home
- INCY vs SSNC Comparison
INCY vs SSNC Comparison
Compare INCY & SSNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- SSNC
- Stock Information
- Founded
- INCY 1991
- SSNC 1986
- Country
- INCY United States
- SSNC United States
- Employees
- INCY N/A
- SSNC N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- SSNC EDP Services
- Sector
- INCY Health Care
- SSNC Technology
- Exchange
- INCY Nasdaq
- SSNC Nasdaq
- Market Cap
- INCY 17.0B
- SSNC 19.9B
- IPO Year
- INCY 1993
- SSNC 1996
- Fundamental
- Price
- INCY $91.48
- SSNC $84.71
- Analyst Decision
- INCY Buy
- SSNC Strong Buy
- Analyst Count
- INCY 19
- SSNC 9
- Target Price
- INCY $81.73
- SSNC $99.89
- AVG Volume (30 Days)
- INCY 1.7M
- SSNC 1.3M
- Earning Date
- INCY 10-28-2025
- SSNC 10-23-2025
- Dividend Yield
- INCY N/A
- SSNC 1.28%
- EPS Growth
- INCY 900.04
- SSNC 20.69
- EPS
- INCY 4.37
- SSNC 3.37
- Revenue
- INCY $4,584,996,000.00
- SSNC $6,148,400,000.00
- Revenue This Year
- INCY $16.41
- SSNC $7.82
- Revenue Next Year
- INCY $10.86
- SSNC $5.30
- P/E Ratio
- INCY $20.90
- SSNC $25.10
- Revenue Growth
- INCY 18.87
- SSNC 6.67
- 52 Week Low
- INCY $53.56
- SSNC $66.83
- 52 Week High
- INCY $92.86
- SSNC $91.07
- Technical
- Relative Strength Index (RSI)
- INCY 67.77
- SSNC 50.97
- Support Level
- INCY $84.38
- SSNC $80.86
- Resistance Level
- INCY $92.86
- SSNC $83.29
- Average True Range (ATR)
- INCY 2.44
- SSNC 1.82
- MACD
- INCY 0.35
- SSNC 0.07
- Stochastic Oscillator
- INCY 86.26
- SSNC 63.18
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About SSNC SS&C Technologies Holdings Inc.
SS&C Technologies provides software products and software-enabled services to a variety of customers primarily in financial services but also healthcare firms. Acquisitions are a large part of SS&C's history. SS&C GlobeOp provides fund administration services to alternative and traditional asset managers. In addition, SS&C provides portfolio accounting, portfolio management, trading, banking/lending, and other software to asset managers, banks, and financial advisors. SS&C's purchase of Intralinks makes it a leading player in virtual deal room solutions. With its 2018 purchase of DST Systems, SS&C gained a foothold in the healthcare industry with pharmacy health management solutions and medical claim administration services. In 2022, SS&C completed the acquisition of Blue Prism.